2 hrs ago | Penny PayDay
Regeneron (Nasdaq: REGN) climbs after raising Eylea sales outlook
Northern, WI 2/13/12 - Shares of Regeneron Pharmaceuticals Inc. jumped Monday after the company predicted much stronger sales of its eye drug Eylea.
6 hrs ago | AmericanBankingNews.com
Regeneron Pharms Share Price Target Raised to $120.00 by Brean Murray Analysts
Analysts at Brean Murray upped their price target on shares of Regeneron Pharms from $100.00 to $120.00 in a research report issued to clients and investors on Monday.
6 hrs ago | BioSpace
Regeneron Pharmaceuticals, Inc. Announces February 13, 2012 as Date...
Regeneron Pharmaceuticals, Inc. Announces February 13, 2012 as Date of Full Year 2011 Financial and Operating Results Conference Call and Webcast Live audio of the conference call will be webcast online simultaneously.
11 hrs ago | The Washington Post
Regeneron Rises on Forecast for Eye Drug Sales: New York Mover
Regeneron Pharmaceuticals Inc. surged in early trading after the company increased its sales forecast for eye drug Eylea higher than analyst estimates.
11 hrs ago | The Washington Post
Diebold, Energen, Jive, Nvidia, Regeneron: U.S. Equity Movers
Shares of the following companies are having unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 9:35 a.m. in New York.
12 hrs ago | Freshnews
Regeneron Reports Fourth Quarter and Full Year 2011 Financial and Operating Results
The Company reported total revenues of $123.0 million for the fourth quarter and $445.8 million for the year ended December 31, 2011.
Regeneron Announces February 13, 2012 as Date of Full Year 2011...
The Company will host a conference call at 8:30 AM EST that day. The February 13, 2012 date is a change from the previously announced date of February 16, 2012.
Big Pharma's Potential Consumer Growth Avenue
Perhaps it is true that any press is good press. No one likes bad press, especially when others in the same field are receiving positive press.
Visa, Pioneer Natural Resources, Rackspace, Regeneron Win 52-Week Price Highs Today
Visa Inc. : Visa announced that U.S. financial institutions have reported issuing an estimated one million Visa-branded, EMV chip-enabled cards as of Dec.
Analysts at BMO Capital Markets downgraded PNC Financial Services Group Inc from "outperform" to "market perform." PNC's shares closed at $62.20 on Friday.
Jefferies Group increased their price target on shares of Regeneron Pharms to $1,111.00 in a research note issued on Monday.
Piper Jaffray Downgrades Regeneron Pharmaceuticals to Neutral
Piper Jaffray lowers it rating on Regeneron Pharmaceuticals to Neutral from Overweight as shares appear over-extended as the stock has overperformed peers year to date.
U.S. Stock Futures Fall as Investors Await Greek Talks Outcome
JPMorgan Chase & Co. and Citigroup Inc. fell. Regeneron Pharmaceuticals Inc. dropped 2.9 percent after the stock was downgraded at Piper Jaffray & Co.
ThinkEquity Analysts Begin Coverage on Regeneron Pharms
Equities research analysts at ThinkEquity initiated coverage on shares of Regeneron Pharms in a research note issued to investors on Friday.
BMO Reduces Peabody Target, Regeneron Progressing, Edwards...
Peabody Energy Corp. : BMO Capital reduced its target on Peabody Energy after the company provided significantly lower than expected Q1 EPS guidance.
Yum!, Regeneron, Seagate Tech, Temple-Inland Among 52-Week High Stocks Today
Yum! Brands : Yum! Brands CEO, David Novak, has managed to turn millions of Chinese into ardent fans of Kentucky-style 'finger-lickin good' chicken, Barron's reports.
Bank of America (BAC) Analysts Upgrade Regeneron Pharms (REGN) Shares to "Buy"
Regeneron Pharms was upgraded by Bank of America to a "buy" rating in a research note issued on Monday.
Regeneron to Report Full Year 2011 Financial and Operating Results...
The Company will host a conference call at 8:30 AM EST that day. Live audio of the conference call will be webcast online simultaneously.
8 Healthcare Stocks Rated Outperform By Robert W. Baird
Interested in the defensive sector of healthcare stocks? If so, here are some ideas to get started on your search.
Analyst Is Skeptical Of Rival Company's Warnings About Regeneron
A Wall Street analyst who says investors should buy shares of Regeneron Pharmaceuticals dismissed concerns raised by another company in an interview with Forbes that Regeneron's new cholesterol drug targeting PCSK9 could be delayed.
Also on Topix